About XtalPi

About Us

About XtalPi

Our Story

XtalPi is an innovative technology company powered by artificial intelligence (AI) and robotics. Founded in 2014 on the MIT campus, XtalPi is dedicated to driving intelligent and digital transformation in the life science and new materials industries. With tightly interwoven quantum physics, AI, cloud computing, and large-scale experimental robotics, XtalPi offers a range of technology solutions, services, and products to accelerate and empower innovation for biopharmaceutical and new materials companies worldwide.

1000+

Employees
700+

Scientists and technologists
180+

Collaboration projects in drug discovery & development
200+

Novel simulation algorithms
100+

Patents
150+

Partners worldwide

XtalPi Global Facilities

Boston

USA

Cambridge Innovation Center (CIC), Kendall Square
XtalPi Boston Site plays a key role in leading the business development efforts for clients in the United States, Europe, and some parts of Asia. The site also collaborates with pharmaceutical companies and scientific research institutions to drive innovation and growth in the industry.
Shenzhen

China

Shenzhen Futian District International Biomedical Industrial Park
Center for corporate operations and main R&D center
Includes a full-scale synthetic chemistry lab, a pharmaceutical solid state R&D Lab and a drug discovery biology lab that together enable drug design and deliver solid-state research under our "A.I. computing + experiment" model.
Site area: 130,000 ft²
Visit XtalPi Shenzhen Dry & Automated Web Lab Online >>
Shanghai

China

Shanghai Free Trade No. 1 Life Science and Technology Industrial Park
XtalPi Shanghai Site offers an all-in-one drug discovery platform for small molecules and biologics, as well as cutting-edged modeling, automated synthetic chemistry, and biology services.
Site area: 65,000 ft²
Visit XtalPi Shanghai Automated Web Lab Online >>

Shanghai Zhangjiang Science City
Center for greater China business operations and development
Beijing

China

Beijing Zhong Guan Cun Science Park (Z-Park)
Committed to driving drug discovery innovation with big data and deep learning algorithms, and providing technology and services for drug discovery.
Site area: 16,000 ft²

History

2015

XtalPi officially established in Shenzhen;

Began developing research platform to study solid-state form of drugs;

Partnered with AWS to build large-scale cloud computing capabilities;

2016

Established a CSP platform for crystal form prediction, leveraging QM and AI;

CSP platform proven accurate in blind test held by Pfizer

AI R&D center officially registered;

2018

Developed XFF high-precision force field and XFEP for free energy perturbatiuon calculations

Established wet lab facilities for solid-state R&D, synthesis and experimental research;

Developed drug discovery platform for small molecules;

2019

Began developing drug discovery platform for antibody, peptide and protein therapeutics

2020

Established Amplified Chemical Synthesis service

2021

Shenzhen Experimental and Computing R&D Center and Shenzhen Futian International Pharmaceutical Industrial Park were completed;

Shanghai Pharmaceutical Innovation R&D Center completed-Shanghai Pudong Free Trade Zone;

Domestic Business Center moved to a new site in Zhangjiang Science City;

2022

Enhanced antibody drug research and development platform;

Established DEL screening technologies;

2015

2016

2018

2019

2020

2021

2022

Founding Team

Wen Shuhao

Co-founder/Chairman

Read More

Ph.D. in Physics, Chinese Academy of Sciences, Postdoctoral Fellow, University of California, Massachusetts Institute of Technology, Adjunct Professor, Zhejiang University;
Rich research experience and theoretical achievements in the fields of computational physics and quantum chemistry, with dozens of papers published in prestigious journals, and his research results have been cited more than 1,900 times;
Science and technology entrepreneurial talents of the National Ten Thousand Talents Program of the Central Organization Department
Ministry of Science and Technology Innovation and Technology Innovation and Entrepreneurship Talent
Shenzhen overseas high-level talents
Fortune magazine "China's 40 Business Elites Under 40"
Co-founded XtalPi and serves as Chairman.
Ma Jian

Co-founder/CEO

Read More

Ph.D. in Physics, Zhejiang University, Postdoctoral Fellow, Massachusetts Institute of Technology;
Rich research experience in quantum information, quantum computing, numerical simulation, and published dozens of papers in prestigious journals;
2019 MIT Science and Technology Review - one of the "35 people under the age of 35 in scientific and technological innovation";
Shenzhen overseas high-level talents;
Shenzhen local leading talents;
Co-founded XtalPi and serves as CEO.
Lai Lipeng

Co-founder/Chief Innovation Officer

Read More

Double B.S. in Physics and Mathematics from Peking University, Ph.D. in Physics from the University of Chicago, Postdoctoral Fellow at massachusetts Institute of Technology;
Have a deep understanding of the development and operation of pharmaceutical-related software, and have published numerous papers in prestigious journals;
Shenzhen overseas high-level talents;
Co-founded XtalPi and serves as Chief Innovation Officer.

Honors and Awards

National high-tech enterprise
Postdoctoral Innovation Practice Base

Shenzhen academician (expert) workstation
Shenzhen Artificial Intelligence Drug Discovery-Engineering Research Center

ISO27001 Information Security Management System Certification
ISO9001 Quality Management System Certification

IP management system certification
2022 Global Biomedical Technology

2021 Forbes “China Top 50 Technological Enterprises”
2021 Venture50 Top 50 / Venture50 Top 50 Digital Technology

2021 “Star of the Future”, one of 21 high-growth innovation companies in 2021
2020 MIT Technology Review Annual

2020 Deloitte Technology Fast 20 Shenzhen
2020 EY Fudan - China's Most Promising Seed Enterprise

2020 CBInsights Digital Health 150 Digital HealthCare Companies That Transform the Future of Healthcare
2020 36Kr The king of new infrastructure - TOP50 enterprises in the FIELD of AI

Sustainable Development

XtalPi’s mission is to help our partners discover and develop better therapies for patients faster by leveraging the latest in technological advances. In so doing, we expect to help deliver much needed treatments to patients with unmet medical needs. Our technology platform also helps to improve efficiency and productivity over the traditional R&D process, reducing wastes from unnecessary experiments and contributing to a more sustainable business.

We hope to build a healthier tomorrow for everyone, and the planet.

Case Study

Helping Pfizer accelerate development of novel COVID-19 oral antiviral drug PAXLOVID

PAXLOVID is the world's first FDA-approved oral COVID-19 drug developed by Pfizer and sold around the world. To expedite the development of PAXLOVID (PF-07321332), Pfizer and XtalPi worked closely together, combining XtalPi's digital prediction algorithm and experimental validation. It took only six weeks for the teams to complete mutual validation and precise matching of drug crystal structure prediction against the experimental results, making possible the subsequent development and production.

XtalPi's computational prediction provided powerful evidence of the crystal structure designed by Pfizer being the most stable crystal structure under room temperature, thus making it suitable for scale-up and production. In this way CMC scientists were able to rapidly make research decisions and begin the process without delay.

As an oral drug, PAXLOVID was developed in solid state to facilitate storage and transportation. Patients can self-administer the drug at home, leading to greater compliance, thus helping to alleviate the tremendous strain on the medical system at the height of the COVID-19 pandemic.